Published in Virulence on July 26, 2016
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18
The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA (2002) 15.59
Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med (2011) 5.21
Determinants of HIV-1 shedding in the genital tract of women. Lancet (2001) 5.10
Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med (1999) 4.12
Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS (2003) 2.97
Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet (1997) 2.88
The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis (2001) 2.79
Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS (2000) 2.61
Detection of HIV DNA in cervical and vaginal secretions. Prevalence and correlates among women in Nairobi, Kenya. JAMA (1993) 2.41
Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS (2010) 2.33
Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 2.29
The vaginal microbiota and susceptibility to HIV. AIDS (2014) 2.24
Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis (1999) 2.07
Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings. Sex Transm Dis (2008) 2.06
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS (2003) 1.45
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther (2011) 1.33
Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis (2010) 1.22
Correlates of HIV-1 genital shedding in Tanzanian women. PLoS One (2011) 1.19
Cervicovaginal human immunodeficiency virus secretion and plasma viral load in human immunodeficiency virus-seropositive women. Obstet Gynecol (1997) 1.14
Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy. J Acquir Immune Defic Syndr (2003) 1.10
Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding. J Acquir Immune Defic Syndr (2012) 1.03
Switzerland: statement on sexual transmission of HIV by people on ART. HIV AIDS Policy Law Rev (2008) 0.92
Effect of treatment of asymptomatic bacterial vaginosis on HIV-1 shedding in the genital tract among women on antiretroviral therapy: a pilot study. Clin Infect Dis (2009) 0.92
HIV-1 genital shedding is suppressed in the setting of high genital antiretroviral drug concentrations throughout the menstrual cycle. J Infect Dis (2014) 0.89
Cervicovaginal HIV-1 shedding in women taking antiretroviral therapy in Burkina Faso: a longitudinal study. J Acquir Immune Defic Syndr (2014) 0.88
A cross-sectional study of bacterial vaginosis, intravaginal practices and HIV genital shedding; implications for HIV transmission and women's health. BMJ Open (2015) 0.81
HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir. Antivir Ther (2014) 0.79
Persistent genital tract HIV-1 RNA shedding after change in treatment regimens in antiretroviral-experienced women with detectable plasma viral load. J Womens Health (Larchmt) (2013) 0.77